Skip to main content
Vivesto logo

Vivesto — Investor Relations & Filings

Ticker · VIVE ISIN · SE0000722365 LEI · 5493003TZPR4B7QO9L49 ST Manufacturing
Open in API
Filings indexed 1,069 across all filing types
Latest filing 2018-12-14 AGM Information
Country SE Sweden
Listing ST VIVE

About Vivesto

https://www.vivesto.com/en/

Vivesto is a specialty pharmaceutical company focused on drug development in oncology. The company aims to provide new therapeutic options for patients suffering from hard-to-treat cancers where significant medical needs exist. Its research and development efforts are centered on creating innovative treatments and enhancing the intravenous delivery of established and novel drugs. The company's lead product is Apealea, a formulation of the cancer drug paclitaxel.

Recent filings

Filing Released Lang Actions
KALLELSE TILL EXTRA BOLAGSSTÄMMA I OASMIA PHARMACEUTICAL AB (PUBL)
AGM Information Classification · 98% confidence The document is explicitly titled "KALLELSE TILL EXTRA BOLAGSSTÄMMA I OASMIA PHARMACEUTICAL AB (PUBL)" which translates to 'NOTICE OF EXTRAORDINARY GENERAL MEETING IN OASMIA PHARMACEUTICAL AB (PUBL)'. It details the date, time, location, registration procedures, and the proposed agenda for the meeting, which includes electing the board of directors. This content directly corresponds to the purpose of an Annual General Meeting (AGM) or Extraordinary General Meeting (EGM) material. Since the definition for AGM-R covers 'Presentations and materials shared during the Annual General Meeting (AGM)', and this is a formal notice for an EGM (which shares the same procedural nature), AGM-R is the most appropriate classification. It is not a proxy statement (PSI) as it is the notice itself, not the solicitation material for voting recommendations, nor is it a DVA (Declaration of Voting Results) as it precedes the meeting.
2018-12-14 Swedish
Major Shareholding Notification 2018
Major Shareholding Notification Classification · 98% confidence The document details a change in shareholding ('Sell' transaction) by a major holder (Avanza Bank Holding AB for Försäkringsaktiebolaget Avanza Pension) in Vivesto AB. It explicitly lists the number of shares and the resulting percentage of voting rights, referencing limits (10%) and providing a date (04/12/2018). This structure—reporting changes in significant ownership thresholds—is characteristic of a Major Shareholding Notification. The code for this is MRQ.
2018-12-05 English
Major Shareholding Notification 2018
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding, specifically noting a 'Reason for major shareholding notification Buy' and providing exact figures for shares held before and after the transaction, along with the resulting percentage (10.01455%). This structure is characteristic of a notification regarding a significant change in ownership interest in a company's stock. Reviewing the definitions, 'Major Shareholding Notification' aligns perfectly with the code MRQ (Major Shareholding Notification). The document is short and contains specific transactional data, not a general announcement of a report.
2018-12-04 English
Major Shareholding Notification 2018
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding percentage for a specific holder (Avanza Bank Holding AB for Försäkringsaktiebolaget Avanza Pension) in the issuer (Vivesto AB). It explicitly lists 'Reason for major shareholding notification' and provides 'Before the transaction' and 'After the transaction' figures, culminating in a 'Group total holdings' percentage (9.96%). This structure perfectly matches the definition of a Major Shareholding Notification, which is classified as 'MRQ'. The document is a direct notification of ownership change, not an announcement of a report (RPA) or a general regulatory filing (RNS).
2018-12-03 English
Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)
Share Issue/Capital Change Classification · 100% confidence The document details a change in the total number of shares and votes in Oasmia Pharmaceutical AB due to the conversion of convertible loans into shares. This is a direct announcement of a change in share capital and total voting rights, which falls under the category of share issues or capital changes.
2018-11-30 English
Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document is a press release dated November 30, 2018, announcing a 'Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)'. It details the conversion of convertible loans into new shares, resulting in an increase in the total number of shares and the share capital. This directly relates to changes in the company's capital structure due to financing activities (conversion of debt to equity). This aligns best with the 'Capital/Financing Update' category (CAP), as it is a direct consequence of a financing mechanism being executed. It is not a general regulatory filing (RNS) because it is highly specific to capital structure change, nor is it a share repurchase (POS) as it involves issuance via debt conversion.
2018-11-30 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.